top of page
Executive Spotlights

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

New York, NY, December 15, 2022 (PRNewswire) -- Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health disorders, today announced the closing of a $39 million Series B round of financing. The round was led by Prime Movers Lab with additional investment from Alumni Ventures, Palo Santo, Negev Capital, Route 66, JLS Fund, Satori Capital and Gron Ventures. The additional capital will be used, in part, to further advance Gilgamesh's 2 lead programs, GM-1020 and GM-2505 through Phase 1/1b safety and efficacy studies.

Read full article here.

Recent Posts

See All

Rahway, NJ & Cambridge, MA, November 21, 2023 (Business Wire) -- Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. declare a definitive agr

Life Science Headlines
bottom of page